ID
45203
Beschrijving
Principal Investigator: Jonathan Rosand, MD, MSc, Massachusetts General Hospital, Boston, MA, USA MeSH: Intracranial Hemorrhage,Angiopathy, Cerebral Amyloid,Amyloid Angiopathy, Cerebral,Sporadic Cerebral Amyloid Angiopathy,Hemorrhage, Hypertensive Intracranial,Hypertensive Intracranial Hemorrhages https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000416 This is a prospective, longitudinal cohort study of spontaneous ICH. Subjects were recruited from among consecutive patients ≥ 55 years old who presented with primary hemorrhage to the Massachusetts General Hospital or one of our off-site collaborators from 1999 to 2010. Potential subjects were identified by screening lists of all admissions to the neurology and neurosurgery inpatient services. All patients underwent routine clinical evaluation, including history taking and physical examination, laboratory testing, and computed tomography of the brain.
Link
Trefwoorden
Versies (2)
- 17/08/22 17/08/22 - Chiara Middel
- 12/10/22 12/10/22 - Adrian Schulz
Houder van rechten
Jonathan Rosand, MD, MSc, Massachusetts General Hospital, Boston, MA, USA
Geüploaded op
12 ottobre 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000416 Genetics of Cerebral Hemorrhage with Anticoagulation (GOCHA)
The subject consent data table includes subject IDs, consent group information, and subject aliases.
- StudyEvent: SEV1
- The subject consent data table includes subject IDs, consent group information, and subject aliases.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs and sample aliases. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- The subject phenotype data table includes demographic information (n=8 variables; country and year of birth, age, sex, race, ethnicity, cohort, and consenting institute), ICH (n=5 variables; case control status for ICH, location, year, number of hemorrhages, and baseline volume), medical history (n=3 variables; hypertension, diabetes, and hyperlipidemia), lab measurements of coagulation (n=3 variables; PT, INR, and platelets), medication use and dose (n=17 variables; warfarin, heparin, other anticoagulant, aspirin, streptokinase, clopidogrel, ticlodipine, prasugrel, and other antiplatelet), and smoking status.
- This sample attributes data table includes body site where sample was collected, analyte type, and tumor status.
Similar models
The subject consent data table includes subject IDs, consent group information, and subject aliases.
- StudyEvent: SEV1
- The subject consent data table includes subject IDs, consent group information, and subject aliases.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs and sample aliases. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- The subject phenotype data table includes demographic information (n=8 variables; country and year of birth, age, sex, race, ethnicity, cohort, and consenting institute), ICH (n=5 variables; case control status for ICH, location, year, number of hemorrhages, and baseline volume), medical history (n=3 variables; hypertension, diabetes, and hyperlipidemia), lab measurements of coagulation (n=3 variables; PT, INR, and platelets), medication use and dose (n=17 variables; warfarin, heparin, other anticoagulant, aspirin, streptokinase, clopidogrel, ticlodipine, prasugrel, and other antiplatelet), and smoking status.
- This sample attributes data table includes body site where sample was collected, analyte type, and tumor status.
C3847505 (UMLS CUI [1,2])
C1277697 (UMLS CUI [1,3])
C0449416 (UMLS CUI [1,2])
C3847505 (UMLS CUI [1,3])